Uncategorized

May 15, 2026 This week’s developments across the biotechnology and pharmaceutical sector highlight an industry being shaped by renewed investor confidence, expanding therapeutic innovation, and increasingly complex global operating conditions. Momentum continued to build across areas such as oncology, metabolic disease, nephrology, and radiopharmaceuticals, while broader economic and geopolitical pressures continued to influence supply chains, […]

May 8, 2026 This week’s developments across the biotechnology and pharmaceutical sector reflect a landscape being shaped simultaneously by scientific advancement, capital deployment, and increasing external disruption. While innovation continues to accelerate across oncology, obesity, and rare disease, companies are also navigating a more complex backdrop defined by geopolitical instability, shifting policy priorities, and intensifying

May 1, 2026 This week, we look at a broad and evolving mix of strategic transactions, clinical progress, capital flows, and policy developments shaping the global biotechnology and pharmaceutical landscape. Momentum continues to build across high-growth therapeutic areas such as obesity, neuroscience, and immunology, while external forces, including pricing reform, global health funding constraints, and

Clinical Trials Day: Progress, Pressure, and the Talent Behind Modern Clinical Development 20th May, – Green Life Science Introduction International Clinical Trials Day, observed each year on May 20th, marks a defining moment in medical history. In 1747, Scottish physician James Lind conducted one of the first controlled clinical studies, demonstrating that citrus fruits could

10th April 2026 Developments across the global biotechnology and pharmaceutical sector this week highlight an increasingly complex and interconnected environment, shaped by scientific progress, strategic transactions, regulatory oversight, and geopolitical dynamics. Activity spanned acquisitions, licensing agreements, capital markets events, clinical and safety updates, as well as manufacturing investment and supply chain disruption. Taken together, these